London
· Delayed Price · Currency is GBP · Price in EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of GBP 127.33 million. The enterprise value is 112.81 million.
| Market Cap | 127.33M |
| Enterprise Value | 112.81M |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +23.04% |
| Shares Change (QoQ) | +21.39% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 25.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.98 |
| EV / Sales | 3.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -86.91 |
Financial Position
The company has a current ratio of 1.42
| Current Ratio | 1.42 |
| Quick Ratio | 1.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -32.11 |
| Interest Coverage | -2.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.02% |
| Return on Capital (ROIC) | -101.38% |
| Revenue Per Employee | 325,285 |
| Profits Per Employee | -257,991 |
| Employee Count | 102 |
| Asset Turnover | 0.66 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.14% in the last 52 weeks. The beta is 1.32, so Nanobiotix's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | -54.14% |
| 50-Day Moving Average | 3.23 |
| 200-Day Moving Average | 4.67 |
| Relative Strength Index (RSI) | 54.08 |
| Average Volume (20 Days) | 615 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of GBP 35.78 million and -28.38 million in losses. Loss per share was -0.66.
| Revenue | 35.78M |
| Gross Profit | 35.78M |
| Operating Income | -18.98M |
| Pretax Income | -28.16M |
| Net Income | -28.38M |
| EBITDA | -18.90M |
| EBIT | -18.98M |
| Loss Per Share | -0.66 |
Balance Sheet
The company has 56.24 million in cash and 41.69 million in debt, giving a net cash position of 14.55 million.
| Cash & Cash Equivalents | 56.24M |
| Total Debt | 41.69M |
| Net Cash | 14.55M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -18.46M |
| Book Value Per Share | -0.39 |
| Working Capital | 20.30M |
Cash Flow
In the last 12 months, operating cash flow was -879,189 and capital expenditures -418,823, giving a free cash flow of -1.30 million.
| Operating Cash Flow | -879,189 |
| Capital Expenditures | -418,823 |
| Free Cash Flow | -1.30M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -53.06% and -79.31%.
| Gross Margin | 100.00% |
| Operating Margin | -53.06% |
| Pretax Margin | -78.69% |
| Profit Margin | -79.31% |
| EBITDA Margin | -52.83% |
| EBIT Margin | -53.06% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.04% |
| Shareholder Yield | -23.04% |
| Earnings Yield | -22.29% |
| FCF Yield | -1.02% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -3.97. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.97 |
| Piotroski F-Score | n/a |